Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymer-stabilized amorphous CuO-ZnO hybrid nanocomplex as a promising candidate for antimicrobial therapy and controlled drug delivery with molecular docking insights.

Scientific reports·2026
Same author

The APOA1-SNCA Axis as a Molecular Bridge Between CKD and Parkinson's Disease: A Systems Biology Model of Kidney-to-Brain Propagation via Exosomal Pathways.

International journal of molecular sciences·2026
Same author

Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality.

Nature communications·2026
Same author

Integrative computational analysis of Marburg virus protein mutations: structural and functional implications of Glycoprotein variants and natural inhibitor screening.

Journal of biomolecular structure & dynamics·2026
Same author

Structure-Based Virtual Screening of Plant-Derived Flavonoids as Putative GLUT9 Binders with Antioxidant Properties.

Molecules (Basel, Switzerland)·2026
Same author

Genomic and Immunoinformatics Insights Into a Bovine-Derived Brucella abortus S19 Field Strain: Adaptations Impacting Vaccine Efficacy.

Veterinary medicine and science·2025

Related Experiment Video

Updated: Jul 16, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Rethinking Alzheimer's Disease Therapy: From Amyloid-Centric Approaches to Multi-Target Phytochemical Strategies.

Emre Aktaş1, İlay Yurt1, Yağmur Nisa Cerlet1

  • 1Faculty of Art and Science, Molecular Biology and Genetics, Yıldız Technical University, Istanbul, Türkiye.

Journal of Neurochemistry
|July 14, 2026
PubMed
Summary

Multi-target phytochemicals offer a promising approach for Alzheimer's disease (AD) therapy by addressing complex pathology. These plant-derived compounds modulate multiple pathways, unlike single-target drugs, suggesting a more effective treatment paradigm for AD.

Keywords:
Alzheimer's diseaseamyloid‐βdisease‐modifying strategiesmulti‐target therapyneuroinflammationoxidative stressphytochemicalstau pathology

Related Experiment Videos

Last Updated: Jul 16, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is the primary cause of dementia, involving neuronal loss and cognitive decline due to amyloid plaques and tau tangles.
  • Current antibody therapies reduce amyloid but offer modest benefits with safety concerns like ARIA.
  • Existing single-target drugs are insufficient for AD's multifactorial nature.

Purpose of the Study:

  • Critically evaluate limitations of amyloid-centric AD therapies.
  • Contrast these with multi-target phytochemical approaches.
  • Present a mechanistic framework for plant-derived compounds in AD treatment.

Main Methods:

  • Synthesize experimental and translational evidence on phytochemicals.
  • Analyze mechanisms of action including BACE1 inhibition, tau homeostasis, neuroinflammation, oxidative stress, and synaptic integrity.
  • Review systems-level modulation by plant compounds like flavonoids and polyphenols.

Main Results:

  • Phytochemicals act as systems-level modulators, not just symptomatic agents.
  • Compounds coordinate actions on amyloid processing, tau regulation, neuroinflammation, antioxidant defenses (Nrf2), and synaptic preservation.
  • Evidence supports phytochemicals as a biologically congruent therapeutic paradigm for AD.

Conclusions:

  • Multi-target phytochemical strategies represent a neurologically relevant approach for Alzheimer's disease.
  • Future AD therapy may involve integrating phytochemicals into polypharmacological and multidomain frameworks.
  • Combining phytochemicals with lifestyle changes and other therapies requires rigorous validation.